MIFH
KRYS icon

Migdal Insurance & Financial Holdings’s Krystal Biotech KRYS Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,640
Closed -$974K – 633
2021
Q1 		$974K Buy
12,640
+7,844
+164% +$570K 0.01% 243
2020
Q4 		$288K Buy
+4,796
New +$240K ﹤0.01% 269

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Migdal Insurance & Financial Holdings's KRYS Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Krystal Biotech (KRYS) in Q2 2021, closing a stake of 12,640 shares — an estimated $974K sold.

Migdal Insurance & Financial Holdings first reported a position in KRYS in Q4 2020 and held it in 2 quarters. The position peaked at $974K in Q1 2021. 113 funds tracked by Wall St. Rank hold KRYS as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Krystal Biotech position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 12,640 Krystal Biotech shares in Q2 2021, an estimated $974K.
  • Migdal Insurance & Financial Holdings first reported a position in Krystal Biotech in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Krystal Biotech position peaked at $974K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.